#donanemab

Donanemab: The Alzheimer’s Drug That’s Actually Clearing Plaques From Living Brains

A landmark case study shows successful amyloid-beta removal in real patients, not just in a lab. Dr. Andres Zuleta, MD breaks down what it…

Anti-Amyloid Drugs in Alzheimer’s: Breakthrough, Dead End, or Reimbursement Reality Check?

The last few months, and indeed weeks, have seen a sharp change in attitudes towards the anti-amyloid drugs in Alzheimer’s Disease. This is…

Under normal circumstances, the amyloid precursor protein (APP) is broken down by enzymes…

Protein clearance refers to the process where cells eliminate misfolded, damaged, or excess proteins to maintain protein homeostasis. A…

Breaking New Ground in Alzheimer’s Treatment: A Deep Dive into Lilly’s Kisunla™ (Donanemab-azbt)…

The recent FDA approval of Lilly’s Kisunla™ (donanemab-azbt) for early symptomatic Alzheimer’s disease marks a monumental breakthrough in…

New Alzheimer’s trial data is out: glimmer of hope?

Experts say it’s a step in the right direction.

Lilly’s Alzheimer’s drug shows 60% decrease in mild impairment during clinical trial

JUST IN: Exciting news on Alzheimer’s research!

Eli Lilly and Company Alzheimer’s Drug Donanemab Slows Cognitive and Functional Decline in Phase 3…

An Alzheimer’s drug developed by Eli Lilly slowed cognitive and functional decline for people with early stages of the disease. This is…

Alzheimer’s disease is the most common degenerative brain disease that causes dementia and was…

Donanemab Treatment

Revolutionizing Alzheimer's Therapy: Donanemab

Written by: Margo Le. Edited by: Ryan Hobbib and @ana